Developing a Quality Improvement Framework to Enhance the Health System User Experience for Individuals Living With Type 1 Diabetes: The Reshape T1D Study - Boisvenue - 2025 - Health Expectations - Wiley Online Library

Type 1 diabetes with kidney disease? @alberta diabetes has two studies testing new medicines to prevent kidney failure

Type 2 diabetes on metformin? @AlbertaDiabetes are recruiting for a study testing next generation medicines like ozempic

@doreen_rabi @JenLeeCBC People on pumps, basal bolus injections or premixed insulins. AISH, Seniors, or non-Group Blue Cross (Group 1) Info re non-group blue cross here

Great news for people in AB with #diabetes CGM coverage now open to adults, seniors and those on AISH It also opens up opportunities for Automated Insulin Delivery

@SoleimanpourLab @cortig @bcellorg @JamesLyon9 Congrats. Very exciting for @AlbertaDiabetes to partner with you

is Business/Casual the same as Business Casual?

18-29 years and living with #T1D in ON? You might be interested in this. Designed in partnership with diabuddies

We also need to revisit recommendations which have been extrapolated from T2D eg statin recommendations - perhaps using observational data to check our assumptions

Oh yes, we also recommended AID for all (adults and kids) T1D (who want it) Grade A, Level 1a recommendation. Now the advocacy to ensure access that is equitable …

@nictitate @DiabetesCanada Awesome to have great researchers and clinicians at the same meeting. Hopefully enough interest for everyone AND start forging connections and breaking down silos Diabetes is complex. Needs networks and different perspectives if we are to have impact

Dr Rebecca Hull-Meichle from ⁦@AlbertaDiabetes and CERC⁩ making her first presentation at ⁦@DiabetesCanada. What a great talent acquired to advance research in 🇨🇦 ⁦@UAlberta_FoMD⁩ @RebeccaLHull⁩

@ShivaniM_KC Wait for the full text. The evidence for A1c, weight and insulin dose reductions is level 1A. The grade D recommendation is because of uncertainty about who will benefit and recognizing uncertainty re balance of risk and harm

@Abdul_stock A real risk - hence need for risk mitigation. But PWD live with risk everyday (eg hypo). For many years DKA risk was the objection to pumps. Continuous ketone monitoring will be here before you know it and could help mitigate risk

@AliceYYCheng @ShivaniM_KC @DiabetesCanada @CSEM_SCEM Which were yours?

We don’t have good data. We don’t necessarily restrict to high BMI. We hope having a recommendation will facilitate access to drugs for individuals who would like to use them. The evidence is strong but there is uncertainty about who will benefit and how risks are perceived

2 words that I think will be the themes we need to tackle in #diabetes in the next 5-10 years 1. Gatekeeping 2. Heterogeneity Relevant for both clinical and preclinical domains

Delighted to hear the shoutout for IsletCore from @AlbertaDiabetes @bcellorg providing human #islets for some of the work presented by @JCampbellLab at @DiabetesCanada conference